Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1682P - Development of an ex vivo RNA-based predictive assay for tumor tissue explants

Date

10 Sep 2022

Session

Poster session 06

Topics

Laboratory Diagnostics;  Pathology/Molecular Biology;  Translational Research;  Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Evgeny Imyanitov

Citation

Annals of Oncology (2022) 33 (suppl_7): S758-S771. 10.1016/annonc/annonc1078

Authors

E. Imyanitov, P. Kaidun, A.O. Ivantsov, A. Venina, S. Baskina, A. Togo, S. Aleksakhina

Author affiliations

  • Department Of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1682P

Background

Tumor tissue explants are an attractive tool for personalized predictive tests, however their use is compromised by subjective nature of morphological assessment of drug response. We aimed to identify reporter genes, which rapidly change their level of expression in drug-sensitive but not in drug-resistant tumors.

Methods

Fresh tumor tissues were obtained from patients with non-small cell lung cancer (NSCLC) undergoing surgery. Tumor 0.4-mm-thick slices were generated with a tissue chopper. NSCLC explants were cultured for 24 hours in a standard media containing either 8 or 16 mkg/ml of gefitinib or no drug (control). NGS-based transcriptome analysis was performed for explants from EGFR-mutated (n = 4) and non-mutated (n = 5) tumors before and after gefitinib exposure.

Results

Thirty genes were responsive to gefitinib exposure in EGFR-mutant but not in the EGFR wild-type tumor tissue explants. There were several genes demonstrating evident up-regulation in drug responders, e.g., HSPA1A (a member of the heat shock protein 70 family), RSPO3 (a component of receptor tyrosine kinase signaling pathways) and CDKN1C (a tumor suppressor gene capable of causing cell cycle arrest). Some genes were downregulated in response to gefitinib in drug-sensitive tumors, e.g., MUC13, which contributes to lung cancer progression via activation of the ERK/JNK/p38 signaling cascade. The obtained data were replicated by PCR tests both in samples analyzed by RNAseq and in additional lung tumors.

Conclusions

This study revealed a number of gefitinib-responsive genes, which may serve as RNA markers of drug sensitivity in an ex vivo assay. Appropriately designed PCR tests can potentially be used for the analysis of small tumor samples, e.g., tissue biopsies. It remains to be studied, whether the suggested approach is feasible for the prediction of tumor sensitivity to other targeted and cytotoxic drugs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Ministry of Science and Higher Education of the Russian Federation [grant No 075-15-2020-789].

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.